Biotech firm Novavax says its COVID-19 vaccine was more than 90% effective in a phase three trial conducted in the U.S. and Mexico.
The company is now planning to apply for authorisation in the U.S. and Europe.
Our Washington correspondent Giles Gibson reports.
IN: "The Novavax trial…"
OUT: "...Giles Gibson, Washington."
DUR: 36 seconds